Breast ductal carcinoma in situ: A literature review of adjuvant hormonal therapy

Stephen Kinsey-Trotman, Zumin Shi, Beverley Fosh

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Metaanalysis of three studies showed a relative risk of 0.69 (95% confidence interval, 0.60-0.79, P<0.05) for breast malignancies with tamoxifen treatment in a mixed radiotherapy treatment/naïve cohort. Subgroup analysis of DCIS populations in multiple studies showed a trend to benefit with aromatase inhibitor treatment.

Original languageEnglish
Pages (from-to)60-64
Number of pages5
JournalOncology Reviews
Issue number2
Publication statusPublished or Issued - 2016


  • Adjuvant
  • Aromatase inhibitor
  • Breast cancer
  • Ductal carcinoma in situ
  • Hormonal
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this